Home/Filings/4/0001415889-24-029162
4//SEC Filing

Chakma Justin 4

Accession 0001415889-24-029162

CIK 0001671858other

Filed

Dec 11, 7:00 PM ET

Accepted

Dec 12, 5:41 PM ET

Size

8.8 KB

Accession

0001415889-24-029162

Insider Transaction Report

Form 4
Period: 2024-12-10
Chakma Justin
Chief Business Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2024-12-10$0.84/sh+50,000$42,000186,380 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2024-12-1050,0000 total
    Exercise: $0.84Exp: 2029-07-04Common Stock (50,000 underlying)
  • Sale

    Common Stock

    2024-12-10$13.15/sh50,000$657,625136,380 total
Footnotes (2)
  • [F1]The weighted average sale price for the transaction reported was $13.1525, and the range of prices were between $12.95 and $13.42. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
  • [F2]Immediately exercisable.

Issuer

ARS Pharmaceuticals, Inc.

CIK 0001671858

Entity typeother

Related Parties

1
  • filerCIK 0001951238

Filing Metadata

Form type
4
Filed
Dec 11, 7:00 PM ET
Accepted
Dec 12, 5:41 PM ET
Size
8.8 KB